Orgenesis Inc (ORGS) 0.5889 $ORGS Orgenesis to Present

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Orgenesis Inc (ORGS) 0.5889 $ORGS

Orgenesis to Present at the 16th Annual B. Riley Investor Conference
Marketwired - Thu May 07, 12:42PM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Ms. Vered Caplan, CEO of Orgenesis, will present on Tuesday, May 12th at 10:00 a.m. Pacific Time at the 16th Annual B. Riley & Co. Investor Conference to be held at the Loews Hollywood Hotel in Los Angeles, California from May 12 - 14, 2015. Ms. Caplan will be available for one-on-one meetings during the event.

Investment Fund Manager, Chris Buyse, Appointed to Orgenesis Board
Marketwired - Thu Apr 16, 9:00AM CDT
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Chris Buyse has been appointed to the Orgenesis board of directors.

CEO of MaSTherCell, Hugues Bultot, Joins Orgenesis Board of Directors
Marketwired - Wed Apr 15, 9:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced the appointment of Hugues Bultot to its board of directors.
PLL: 123.70 (-0.05)

Orgenesis Signs Cell Therapy Product Development Memorandum of Understanding with CureCell of Korea
Marketwired - Wed Apr 08, 12:25PM CDT
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced it has entered a non-binding memorandum of understanding (MOU) with Korean company CureCell Co., Ltd.

Orgenesis to Collaborate With the Global Stem Cell & Regenerative Medicine Acceleration Center of Korea
Marketwired - Tue Apr 07, 1:27PM CDT
Orgenesis Inc. (OTCQB: ORGS) a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced it has signed a collaboration (MOU) with the Global Stem Cell & Regenerative Medicine Acceleration Center (GSRAC) commissioned by Ministry of Health and Welfare of Korea.

Orgenesis Appoints Itamar Raz as Newest Member of Board of Advisors
Marketwired - Mon Mar 16, 7:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Professor Itamar Raz has been appointed to the Orgenesis board of advisors.

Organesis acquires Belgian cell therapy manufacturer
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 9:05AM CDT


Orgenesis Acquires Cell Therapy Manufacturer MaSTherCell
Marketwired - Mon Mar 09, 5:00AM CDT
Orgenesis Inc. (OTCQB: ORGS) ("Orgenesis" or the "Company", a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes, today announced the Company's plan to increase its global presence and capabilities by acquiring MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics, based in Gosselies, Belgium.

Orgenesis and Pall Corporation Receive $800,000 Grant From BIRD Foundation for Diabetes Research and Development
Marketwired - Mon Jan 26, 7:49AM CST
Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that Orgenesis and Pall Corporation have received an $800,000 grant from the Israel-U.S. Binational Industrial Research and Development ("BIRD" Foundation to finance their current $1,600,000 co-development program.
PLL: 123.70 (-0.05)

Orgenesis Approved for EUR 2.015.000 Grant to Support Development of Its Type 1 Diabetes Program in Europe
Marketwired - Mon Nov 24, 2:21PM CST
Orgenesis SPRL, a subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DG06) for a EUR 2,015 million support program for the research and development of a potential cure for Type 1 Diabetes.

Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes
Marketwired - Wed Oct 15, 6:01AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received a patent for the technology supporting its unique cell-based therapy, which is being developed as a potential cure for Type 1 Diabetes. The U.S. patent No. 8,778,899, was granted for "Methods of Inducing Regulated Pancreatic Hormone Production in Non-pancreatic Islet Tissues" and recognizes the pioneering work done by Dr. Sarah Ferber and the research team at Orgenesis who have used the technology to successfully reprogram human liver cells into glucose-responsive, fully functional Insulin Producing Cells (IPCs).

Scott Carmer Named as CEO of Orgenesis North America
Marketwire - Mon Aug 04, 8:03AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, today announced the appointment of industry veteran Scott Carmer as CEO of the company's North American subsidiary. Carmer has more than 25 years of diverse industry experience within both pharmaceutical and biotech companies.

Orgenesis Signs Agreement With MaSTherCell to Scale Manufacturing of Insulin-Producing Liver Cells to Combat Diabetes
Marketwire - Mon Jul 07, 7:40AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine today announced that its Belgian subsidiary, Orgenesis SPRL, has signed a strategic agreement with MaSTherCell SA of Gosselies, Belgium. Orgenesis believes that the agreement will enable Orgenesis to advance its manufacturing (GMP) process from lab scale to clinical scale as it prepares for Phase I and Phase II clinical trials.

Orgenesis Receives $1.5 Million Term Loan to Help Fund Breakthrough Innovation in Diabetes Research
Marketwire - Wed Jun 25, 7:31AM CDT
Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, announced today that it raised $1.5 million via a senior secured term loan facility.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 165

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 98

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 165

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Navitas Semiconductor Stock Soars on Strong Q4 Performance

Updated Category News Views 257

Climbing Higher: NVTS Takes Off After Solid Earnings Out of nowhere, Navitas Semiconductor is buzzing with energy, and it’s no coincidence. After posting its fourth-quarter results, the stock skyrocketed—up over 25%. A quarterly loss of 5 cents per share? No biggie—it’s right where analysts expected. But that revenue? $7.30 million, cruising past the $6.95 million...

Continue Reading
Exploring the Expanding Sodium Sulfide Market with Insights

Updated Category News Views 126

Overview of the Global Sodium Sulfide Market The global sodium sulfide market is on a promising upward trajectory, with forecasts estimating its size to reach US$ 17.47 billion by 2034. This notable growth is expected to take place at a compound annual growth rate (CAGR) of 4.8% from 2024 through 2034, as outlined in a recent research study. Sodium sulfide finds extensive...

Continue Reading
Discover the Latest Innovations in Cordless Vacuum Technology

Updated Category News Views 207

Discover Tineco's New Cordless Vacuum Models Always innovating, Tineco has unveiled two remarkable cordless vacuum cleaners designed for modern living: the PURE ONE Station 5 and PURE ONE A50S. Both models combine state-of-the-art technology with practical features, making floor cleaning a breeze. With these intelligent vacuums, cleaning becomes a more pleasant...

Continue Reading
Carisma Therapeutics Initiates Voluntary Delisting from Nasdaq

Updated Category News Views 206

Carisma Therapeutics Unveils Delisting Plans from Nasdaq Carisma Therapeutics Inc. (OTCID: CARM) recently announced that its Board of Directors has approved a pivotal decision to voluntarily delist its common stock from The Nasdaq Stock Market LLC. This strategic move is aimed at deregistering the company’s common stock to suspend and ultimately conclude its reporting...

Continue Reading
Bragg's New Pineapple Turmeric Blend: A Refreshing Wellness Choice

Updated Category News Views 358

Bragg's Exciting New Product Launch A Tropical Twist on Bragg's Iconic ACV Hits Shelves Nationwide Introducing the Pineapple Turmeric ACV Blend Bragg Live Food Products, Inc. is making waves by expanding its product variety with a delightful new blend – the Pineapple Turmeric Apple Cider Vinegar (ACV) Blend. This innovative concoction signifies a fresh approach toward...

Continue Reading